INOVIO Submits VOCERYQ Marketing Application to EMA After Accelerated U.S. Approval
Key Facts
INOVIO said it submitted a marketing authorization application to the European Medicines Agency for VOCERYQ to treat adults with recurrent respiratory papillomatosis, moving the treatment into European regulatory review after it received accelerated U.S. approval. The announcement follows the company’s Nov. 10 statement that it planned to submit a European application before the end of 2026. The FDA granted the treatment accelerated approval on Oct. 30 to reduce the frequency of surgery in adults with the disease. The European development puts the treatment before another regulator, while the application remains separate from any decision to approve it. In the United States, accelerated approval was tied to a specific clinical benefit and the need for a confirmatory study.
The FDA approval was based on the RRP-001 study, which evaluated VOCERYQ in 32 adults with recurrent respiratory papillomatosis at multiple clinical sites. The company defined a complete response as no need for surgical intervention during the 12 months after treatment in the efficacy-evaluable population. This highlights the importance of reducing the frequency of surgery for a disease that may require repeated procedures to remove respiratory growths. In the efficacy-evaluable population, the median number of excisions in the 12 months before the first dose was 4.5, with a range of 3 to 8 procedures. These figures provide context for the surgical burden before treatment, while the response measure cited as the basis for approval concerns the period after treatment.
INOVIO said recurrent respiratory papillomatosis is a rare and debilitating disease associated primarily with HPV-6 and HPV-11, causing papillomas to grow in the respiratory tract. Surgery to remove these growths is the standard of care, but their recurrence can make procedures frequent. The company described VOCERYQ as a DNA plasmid-based immunotherapy that encodes antigens for HPV-6 and HPV-11 and is administered using the CELLECTRA device. It said the full clinical data for the treatment were published in 2025, followed by an additional analysis of the data in October 2026. The study supporting approval evaluated the treatment in adults with the disease, while the company put the pre-treatment surgical burden in the efficacy population at a median of 4.5 procedures over a year.
The company is also planning to begin a commercial launch in the United States. It expects VOCERYQ to be available for ordering and shipping about 60 days after the FDA’s Oct. 30 approval, with deployment of the commercial team to be completed during the first quarter of 2027. INOVIO said current inventory and production capacity are expected to support at least the first launch year during 2027. It also hired Syneos Health to support recruitment and deployment of medical and commercial teams. These steps set out a U.S. commercial timeline extending into next year, while the European process remains at the application stage.
The confirmatory study remains a key regulatory milestone in the United States; INOVIO said verification of clinical benefit may require the study. The FDA asked the company to submit a draft protocol by the end of 2026, with a final protocol expected to be agreed by mid-2027. This means accelerated approval does not end the clinical requirements associated with the treatment, and the company is working on the study design alongside the commercial launch. INOVIO presented these dates as expected future steps, not completed outcomes. The European application announcement adds a separate review track to this regulatory timeline.
The company’s financial results show that launch preparations coincided with an increase in selling, general and administrative expenses to $9.2 million in the third quarter of 2026, from $7.9 million in the same period of 2025. INOVIO attributed the increase to the expected launch of VOCERYQ. Cash, cash equivalents and short-term investments totaled $48.4 million on Sept. 30, 2026, compared with $58.5 million on Dec. 31, 2025, before accounting for net proceeds from the November offering. The company said its cash resources would support operations through late in the fourth quarter of 2027, including about $80.5 million in net offering proceeds and $10.9 million from the exercise of warrants after Sept. 30. These figures put launch preparation costs and operating funding in the context of the commercial expansion announced by the company.